Pulmonary delivery of insulin lipid suspension

Yaoxue Xuebao

Volumn 37, Issue 5, 2002, Pages 378-382

  Jiang, Zhi Qiang ^a   Lu, Jian ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Bioavailability; Hypoglycemic effect; Insulin; Lipid suspension; Pulmonary delivery

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; LIPOSOME;

ANIMAL; ARTICLE; BIOAVAILABILITY; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; GLUCOSE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION; MALE; METABOLISM; PARTICLE SIZE; RANDOMIZATION; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SUSPENSION; TRACHEA; WISTAR RAT;

ADMINISTRATION, INHALATION; ANIMALS; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; DRUG DELIVERY SYSTEMS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; LIPOSOMES; MALE; PARTICLE SIZE; RANDOM ALLOCATION; RATS; RATS, WISTAR; SUSPENSIONS; TRACHEA;

EID: 0042383074     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Patton JS, Bukar J, Nagarajan S. Inhaled insulin [J]. Adv Drug Deliv Rev, 1999,35(2-3):235-247.
2. Liu FY, Shao Z, Kildsig DO, et al. Pulmonary delivery of free and liposomal insulin [J]. Pharm Res, 1993,10(2): 228-232.
3. Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery [J]. Science, 1997,276 (20 Jun):1868-1871.
4. Kawashima Y, Yamamoto H, Fujioka S, et al. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect [J]. J Controlled Release, 1999,62(1-2):279-287.
5. Shen Z, Zhang Q, Cui C, et al. Bioavailabilities of insulin aerosol by pulmonary delivery to rats [J]. Acta Pharm Sin, 2000,35(6):465-468.
6. Zhang Q, Shen Z, Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylate nanoparticles after pulmonary administration to normal rats [J]. Int J Pharm, 2001,218(1-2):75-80.
7. Jiang ZQ, Hu TX, Ma YM, et al. Artificial reconstituted pulmonary surfactant used for prevention and treatment of adult respiratory distress syndrome II. Bioluminescence method for optimizing formulation [J]. Acta Pharm Sin, 1997,32(2):123-126.
8. Jiang ZQ, Ma YM, Xi NZ. Artificial reconstituted pulmonary surfactant used for prevention and treatment of adult respiratory distress syndrome III. Prevention in animal model [J]. Acta Pharm Sin, 1997,32(2):127-130.
9. Lu B. New Techniques and New Dosage Forms of Drugs [M]. Beijing: People's Medical Publishing House, 1998.221.
10. Xu SY, Bian RL, Chen X. Methodology of Pharmacological Experiments ($im%&Jï&¥) [M]. 2nd ed. Beijing: People's Medical Publishing House, 1991.1272-1274.
11. Haitsma JJ, Lachmann U, Lachmann B. Exogenous surfactant as a drug delivery agent [J]. Adv Drug Deliv Rev, 2001,47(2-3):197-207.
12. Adjei AL, Gupta PK. Inhalation Delivery of Therapeutic Peptides and Proteins [M]. New York: Marcel Dekker, 1997.667-702.